A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

691

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

April 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide once weekly

2.0mg subcutaneous injection, once a week

DRUG

exenatide twice daily

5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)

Trial Locations (42)

Unknown

Research Site, Beijing

Research Site, Chengdu

Research Site, Chongqin

Research Site, Guangzhou

Research Site, Shanghai

Research Site, Ahmedabad

Research Site, Aligarh

Research Site, Bangalore

Research Site, Ghaziabad

Research Site, Hyderabaad

Research Site, Indore

Research Site, Kolkata

Research Site, Mumbai

Research Site, Pune

Research Site, Trivandrum

Research Site, Uttar Pradesh

Research Site, Varanasi

Research Site, Ageo

Research Site, Chiyoda-ku

Research Site, Izumisano

Research Site, Kashiwara

Research Site, Kitaazumi-gun

Research Site, Kumamoto

Research Site, Kurume

Research Site, Matsumoto

Research Site, Matsuyama

Research Site, Miyazaki

Research Site, Osaka

Research Site, Ōita

Research Site, Ōta-ku

Research Site, Shinjuku-ku

Research Site, Takatsuki

Research Site, Yokohama

Research Site, Bucheon-si

Research Site, Daegu

Research Site, Seoul

Research Site, Changhua

Research Site, Chiayi City

Research Site, Kaohsiung City

Research Site, Tainan City

Research Site, Taipei

Research Site, Taoyuan District

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY